Thelansis

  Breast cancer cells that don’t have abnormal levels of HER2 proteins are to be considered HER2-negative. In the United States, HER2-negative cases accounted for 78% of the newly diagnosed breast cancer and in ~5% to 8% of cases, the HER2 status was unknown. HER2-negative breast cancer represents the largest and most heterogeneous group because it includes both hr-positive tumors. In the case of hr-positive her2-negative metastatic disease, guidelines suggest that endocrine therapy, rather than chemotherapy, should be offered as standard first-line treatment. The treatment of hr-positive her2-negative patients is primarily non-curative with overall 5-year survival rates range between 30% to 45%.   The competitive landscape of HER2-negative Breast Cancer includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of HE...